Compare Ally Financial Inc (ALLY) vs Bristol-Myers Squibb Co (BMY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ally Financial Inc vs Bristol-Myers Squibb Co — how do they compare? Ally Financial Inc trades at $43.77 (market cap $13.37B), while Bristol-Myers Squibb Co trades at $63.78 (market cap $129.94B). The key difference: Bristol-Myers Squibb Co is far larger — about 9.7× Ally Financial Inc's market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| ALLY | BMY | |
|---|---|---|
Market Cap | $13.37B | $129.94B |
Sector | Financials | Health |
52-Week High | $47.25 | $65.89 |
52-Week Low | $35.96 | $42.60 |
Dividend Yield | 2.73% | 3.96% |
Enterprise Value | — | $163.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ally Financial (ALLY) trades at $43.79, showing modest daily gains of 0.16%. The stock presents a compelling valuation with a P/E of 10.34 and P/B of 0.99, trading below analyst consensus target of $54.40. Recent Q2 2026 earnings missed expectations despite revenue growth, while technical indicators show bearish momentum with the stock trading near key support levels. The company maintains strong institutional support with 68% analyst buy ratings and recently declared a $0.30 dividend.
Ally offers value investment potential with attractive valuation metrics and solid dividend yield, though near-term headwinds include recent earnings miss and bearish technical signals. The auto finance business faces credit risk concerns amid economic uncertainty, but long-term digital banking leadership and improving margins provide growth catalysts. Upside potential exists if the company can maintain credit quality while expanding its digital banking footprint.
Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.
The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ally Financial Inc
Ally Financial Inc is a diversified financial services firm that services automotive dealers and their retail customers. The company operates as a financial holding company and a bank holding company. Its banking subsidiary, Ally Bank, caters to the direct banking market through Internet, mobile, and mail. The company reports four business segments including Automotive Finance operations, Insurance operations, Mortgage Finance operations and Corporate Finance operations.
Read more on ALLY →About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →
